Idorsia Pharmaceuticals Ltd: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ad hoc announcement pursuant to Art. 53 LR Idorsia announces financial results for the first nine months of 2022 - QUVIVIQ becoming a global brand Allschwil, Switzerland - October 25, 2022Idorsia
Idorsia Pharmaceuticals Ltd: Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Allschwil, Switzerland - May 10, 2022 Idorsia Ltd (SIX: IDIA) today announced that ACT-539313, a selective orexin-1 receptor antagonist, did not show an improvement over placebo in reducing the number